首页> 外国专利> LARGE-SCALE EPIGENOMIC REPROGRAMMING LINKS ANABOLIC GLUCOSE METABOLISM TO DISTANT METASTASIS DURING THE EVOLUTION OF PANCREATIC CANCER PROGRESSION

LARGE-SCALE EPIGENOMIC REPROGRAMMING LINKS ANABOLIC GLUCOSE METABOLISM TO DISTANT METASTASIS DURING THE EVOLUTION OF PANCREATIC CANCER PROGRESSION

机译:大规模的表观遗传学重新设计将胰腺癌进展过程中的代谢代谢与远处转移联系起来。

摘要

The present invention relates to a method of identifying targets for epigenetic reprogramming comprising detecting large organized heterochromatin lysine (K)-9 modified domains (LOCKs) and large DNA hypomethylated blocks in a sample containing DNA from a subject having cancer, for example, PDAC. The invention also provides for the use of differentially expressed genes to identify metastatic propensity in primary tumors, wherein the genes are selected from genes in the Tables herein, oxidative stress genes, EMT genes, immunological response genes, DNA repair genes, glucose metabolism genes, oxPPP genes, and PGD genes. Further, the invention provides a method for identifying agents or compounds to affect epigenomic changes, including inhibition of oxPPP comprising analyzing a sample from a subject before and after contacting with the agent or compound and determining the effect of the agent or compound on the epigenomic changes.
机译:本发明涉及一种鉴定用于表观遗传重编程的靶标的方法,该方法包括在含有来自患有癌症的受试者例如PDAC的DNA的样品中检测大的有组织的异染色质赖氨酸(K)-9修饰的结构域(LOCK)和大的DNA低甲基化的嵌段。本发明还提供了差异表达的基因在原发性肿瘤中鉴定转移倾向的用途,其中所述基因选自本文表中的基因,氧化应激基因,EMT基因,免疫应答基因,DNA修复基因,葡萄糖代谢基因, oxPPP基因和PGD基因。此外,本发明提供了一种用于鉴定影响表观基因组变化的试剂或化合物的方法,包括抑制oxPPP,包括在与该试剂或化合物接触之前和之后分析来自受试者的样品,并确定该试剂或化合物对表观基因组变化的影响。 。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号